| Year |
Citation |
Score |
| 2024 |
Choi BD, Gerstner ER, Frigault MJ, Leick MB, Mount CW, Balaj L, Nikiforow S, Carter BS, Curry WT, Gallagher K, Maus MV. Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma. The New England Journal of Medicine. PMID 38477966 DOI: 10.1056/NEJMoa2314390 |
0.524 |
|
| 2024 |
Lee WH, Graham CE, Wiggin HR, Nolan HK, Graham KJ, Korell F, Leick MB, Barselau AL, Emmanuel-Alejandro E, Trailor MA, Gildea JM, Preffer F, Frigault MJ, Maus MV, Gallagher KME. Optimization of a flow cytometry test for routine monitoring of B cell maturation antigen targeted CAR in peripheral blood. Cytometry. Part B, Clinical Cytometry. PMID 38418432 DOI: 10.1002/cyto.b.22165 |
0.548 |
|
| 2024 |
Wehrli M, Guinn S, Birocchi F, Kuo A, Sun Y, Larson RC, Almazan AJ, Scarfò I, Bouffard AA, Bailey SR, Anekal PV, Montero Lopis P, Nieman LT, Song Y, Xu KH, ... ... Maus MV, et al. Mesothelin CAR T-cells secreting anti-FAP/anti-CD3 molecules efficiently target pancreatic adenocarcinoma and its stroma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 38393682 DOI: 10.1158/1078-0432.CCR-23-3841 |
0.591 |
|
| 2024 |
Kembuan GJ, Kim JY, Maus MV, Jan M. Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology. Trends in Cancer. PMID 38355356 DOI: 10.1016/j.trecan.2024.01.003 |
0.495 |
|
| 2024 |
Haradhvala NJ, Maus MV. Understanding Mechanisms of Response to CAR T-cell Therapy through Single-Cell Sequencing: Insights and Challenges. Blood Cancer Discovery. 5: 86-89. PMID 38324393 DOI: 10.1158/2643-3230.BCD-23-0212 |
0.5 |
|
| 2024 |
Levine BL, Pasquini MC, Connolly JE, Porter DL, Gustafson MP, Boelens JJ, Horwitz EM, Grupp SA, Maus MV, Locke FL, Ciceri F, Ruggeri A, Snowden J, Heslop HE, Mackall CL, et al. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nature Medicine. PMID 38195751 DOI: 10.1038/s41591-023-02767-w |
0.611 |
|
| 2023 |
Kann MC, Schneider EM, Almazan AJ, Lane IC, Bouffard AA, Supper VM, Takei HN, Tepper A, Leick MB, Larson RC, Ebert BL, Maus MV, Jan M. Chemical genetic control of cytokine signaling in CAR-T cells using lenalidomide-controlled membrane-bound degradable IL-7. Leukemia. PMID 38123696 DOI: 10.1038/s41375-023-02113-6 |
0.487 |
|
| 2023 |
Boucher JC, Shrestha B, Vishwasrao P, Leick M, Cervantes EV, Ghafoor T, Reid K, Spitler K, Yu B, Betts BC, Guevara-Patino JA, Maus MV, Davila ML. Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia. Molecular Therapy Oncolytics. 31: 100751. PMID 38075241 DOI: 10.1016/j.omto.2023.100751 |
0.417 |
|
| 2023 |
Ramos A, Koch CE, Liu-Lupo Y, Hellinger RD, Kyung T, Abbott KL, Fröse J, Goulet D, Gordon KS, Eidell KP, Leclerc P, Whittaker CA, Larson RC, Muscato AJ, Yates KB, ... ... Maus MV, et al. Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screening. Nature Communications. 14: 8048. PMID 38052854 DOI: 10.1038/s41467-023-43790-2 |
0.53 |
|
| 2023 |
Lane IC, Kembuan G, Carreiro J, Kann MC, Lin W, Bouffard AA, Kreuzer J, Morris R, Schneider EM, Kim JY, Zou C, Salas-Benito D, Gasser JA, Leick MB, Słabicki M, ... ... Maus MV, et al. Genetic retargeting of E3 ligases to enhance CAR T cell therapy. Cell Chemical Biology. PMID 37989314 DOI: 10.1016/j.chembiol.2023.10.024 |
0.47 |
|
| 2023 |
Larson RC, Kann MC, Graham C, Mount CW, Castano AP, Lee WH, Bouffard AA, Takei HN, Almazan AJ, Scarfó I, Berger TR, Schmidts A, Frigault MJ, Gallagher KME, Maus MV. Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma. Nature Communications. 14: 7509. PMID 37980341 DOI: 10.1038/s41467-023-43416-7 |
0.528 |
|
| 2023 |
Lareau CA, Yin Y, Maurer K, Sandor KD, Daniel B, Yagnik G, Peña J, Crawford JC, Spanjaart AM, Gutierrez JC, Haradhvala NJ, Riberdy JM, Abay T, Stickels RR, Verboon JM, ... ... Maus MV, et al. Latent human herpesvirus 6 is reactivated in CAR T cells. Nature. PMID 37938768 DOI: 10.1038/s41586-023-06704-2 |
0.527 |
|
| 2023 |
Ruella M, Korell F, Porazzi P, Maus MV. Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies. Nature Reviews. Drug Discovery. 22: 976-995. PMID 37907724 DOI: 10.1038/s41573-023-00807-1 |
0.517 |
|
| 2023 |
Elsallab M, Maus MV. Expanding access to CAR T cell therapies through local manufacturing. Nature Biotechnology. 41: 1698-1708. PMID 37884746 DOI: 10.1038/s41587-023-01981-8 |
0.405 |
|
| 2023 |
Singh N, Maus MV. Synthetic manipulation of the cancer-immunity cycle: CAR-T cell therapy. Immunity. 56: 2296-2310. PMID 37820585 DOI: 10.1016/j.immuni.2023.09.010 |
0.493 |
|
| 2023 |
Kronig MN, Wehrli M, Salas-Benito D, Maus MV. "Hurdles race for CAR T-cell therapy in digestive tract cancer". Immunological Reviews. 320: 100-119. PMID 37694970 DOI: 10.1111/imr.13273 |
0.441 |
|
| 2023 |
Lin Y, Raje NS, Berdeja JG, Siegel DS, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Massaro M, Petrocca F, Yeri A, Finney O, Caia A, Yang Z, et al. Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. Nature Medicine. PMID 37592106 DOI: 10.1038/s41591-023-02496-0 |
0.412 |
|
| 2023 |
Curran KJ, Nikiforow S, Bachier C, Hsu YM, Maloney DG, Maus MV, McCarthy PL, Porter DL, Shi PA, Shpall EJ, William B, Wacker K, Warkentin P, Heslop HE. Robust Quality Infrastructure is Key to Safe and Effective Delivery of Immune Effector Cells: How FACT-Finding Can Help. Blood Advances. PMID 37467016 DOI: 10.1182/bloodadvances.2023010401 |
0.337 |
|
| 2023 |
Maus MV. Signatures of dysfunctional CAR T cells. Blood. 141: 3127-3129. PMID 37383003 DOI: 10.1182/blood.2023020935 |
0.517 |
|
| 2023 |
Pourzia AL, Olson ML, Bailey SR, Boroughs AC, Aryal A, Ryan J, Maus MV, Letai A. Quantifying requirements for mitochondrial apoptosis in CAR T killing of cancer cells. Cell Death & Disease. 14: 267. PMID 37055388 DOI: 10.1038/s41419-023-05727-x |
0.467 |
|
| 2023 |
DeFilipp Z, Maus MV. Linking the microbiome to CAR-T cell responses. Nature Medicine. PMID 36973411 DOI: 10.1038/s41591-023-02272-0 |
0.489 |
|
| 2023 |
Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, Frigault MJ, Hill JA, Jain MD, Johnson WT, Lin Y, Mahadeo KM, Maron GM, Marsh RA, Neelapu SS, ... ... Maus MV, et al. Immune Effector Cell associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS). Transplantation and Cellular Therapy. PMID 36906275 DOI: 10.1016/j.jtct.2023.03.006 |
0.511 |
|
| 2023 |
Leick MB, Maus MV. Multiomics STEP up in correlative analysis of response to CAR T cells. Nature Reviews. Clinical Oncology. PMID 36792726 DOI: 10.1038/s41571-023-00742-5 |
0.439 |
|
| 2022 |
Dupouy S, Marchiq I, Derippe T, Almena-Carrasco M, Jozwik A, Fouliard S, Adimy Y, Geronimi J, Graham C, Jain N, Maus MV, Mohty M, Boissel N, Teshima T, Kato K, et al. Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia. Cancer Research Communications. 2: 1520-1531. PMID 36970059 DOI: 10.1158/2767-9764.CRC-22-0175 |
0.513 |
|
| 2022 |
Schmidts A, Srivastava AA, Ramapriyan R, Bailey SR, Bouffard AA, Cahill DP, Carter BS, Curry WT, Dunn GP, Frigault MJ, Gerstner ER, Ghannam JY, Kann MC, Larson RC, Leick MB, ... ... Maus MV, et al. Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13Rα2 are effective against heterogeneous glioblastoma. Neuro-Oncology Advances. 5: vdac185. PMID 36751672 DOI: 10.1093/noajnl/vdac185 |
0.534 |
|
| 2022 |
Bailey SR, Berger TR, Graham C, Larson RC, Maus MV. Four challenges to CAR T cells breaking the glass ceiling. European Journal of Immunology. e2250039. PMID 36585889 DOI: 10.1002/eji.202250039 |
0.553 |
|
| 2022 |
Hagel KR, Arafeh R, Gang S, Arnoff TE, Larson RC, Doench JG, Mathewson ND, Wucherpfennig KW, Maus MV, Hahn WC. Systematic interrogation of tumor cell resistance to CAR T cell therapy in pancreatic cancer. Cancer Research. PMID 36548402 DOI: 10.1158/0008-5472.CAN-22-2245 |
0.544 |
|
| 2022 |
Irvine DJ, Maus MV, Mooney DJ, Wong WW. The future of engineered immune cell therapies. Science (New York, N.Y.). 378: 853-858. PMID 36423279 DOI: 10.1126/science.abq6990 |
0.35 |
|
| 2022 |
Benjamin R, Jain N, Maus MV, Boissel N, Graham C, Jozwik A, Yallop D, Konopleva M, Frigault MJ, Teshima T, Kato K, Boucaud F, Balandraud S, Gianella-Borradori A, Binlich F, et al. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial. The Lancet. Haematology. PMID 36228643 DOI: 10.1016/S2352-3026(22)00245-9 |
0.477 |
|
| 2022 |
Gaballa MR, Maus MV. High antigen density of BCMA: friend or foe to CAR T cells? Journal For Immunotherapy of Cancer. 10. PMID 36137650 DOI: 10.1136/jitc-2022-005822 |
0.47 |
|
| 2022 |
Haradhvala NJ, Leick MB, Maurer K, Gohil SH, Larson RC, Yao N, Gallagher KME, Katsis K, Frigault MJ, Southard J, Li S, Kann MC, Silva H, Jan M, Rhrissorrakrai K, ... ... Maus MV, et al. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nature Medicine. PMID 36097221 DOI: 10.1038/s41591-022-01959-0 |
0.584 |
|
| 2022 |
Graham CE, Maus MV. CAR T cells Contend with Myeloma in the Bone Marrow Microenvironment. Blood Cancer Discovery. PMID 36026510 DOI: 10.1158/2643-3230.BCD-22-0126 |
0.458 |
|
| 2022 |
Korell F, Berger TR, Maus MV. Understanding CAR T cell-tumor interactions: Paving the way for successful clinical outcomes. Med (New York, N.Y.). 3: 538-564. PMID 35963235 DOI: 10.1016/j.medj.2022.05.001 |
0.532 |
|
| 2022 |
Jing R, Scarfo I, Najia MA, Lummertz da Rocha E, Han A, Sanborn M, Bingham T, Kubaczka C, Jha DK, Falchetti M, Schlaeger TM, North TE, Maus MV, Daley GQ. EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity. Cell Stem Cell. 29: 1181-1196.e6. PMID 35931029 DOI: 10.1016/j.stem.2022.06.014 |
0.56 |
|
| 2022 |
Maus MV. Safety of genetically modified T cells. Blood. 140: 1-2. PMID 35797018 DOI: 10.1182/blood.2022016334 |
0.398 |
|
| 2022 |
Leick MB, Silva H, Scarfò I, Larson R, Choi BD, Bouffard AA, Gallagher K, Schmidts A, Bailey SR, Kann MC, Jan M, Wehrli M, Grauwet K, Horick N, Frigault MJ, ... Maus MV, et al. Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia. Cancer Cell. PMID 35452603 DOI: 10.1016/j.ccell.2022.04.001 |
0.467 |
|
| 2022 |
Larson RC, Kann MC, Bailey SR, Haradhvala NJ, Llopis PM, Bouffard AA, Scarfó I, Leick MB, Grauwet K, Berger TR, Stewart K, Anekal PV, Jan M, Joung J, Schmidts A, ... ... Maus MV, et al. CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours. Nature. 604: 563-570. PMID 35418687 DOI: 10.1038/s41586-022-04585-5 |
0.538 |
|
| 2022 |
Gill SI, Frey NV, Hexner E, Metzger S, O'Brien M, Hwang WT, Brogdon JL, Davis MM, Fraietta JA, Gaymon A, Gladney WL, Lacey SF, Lamontagne A, Mato AR, Maus MV, et al. Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia. Blood Advances. PMID 35349631 DOI: 10.1182/bloodadvances.2022007317 |
0.514 |
|
| 2022 |
Joung J, Kirchgatterer PC, Singh A, Cho JH, Nety SP, Larson RC, Macrae RK, Deasy R, Tseng YY, Maus MV, Zhang F. CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity. Nature Communications. 13: 1606. PMID 35338135 DOI: 10.1038/s41467-022-29205-8 |
0.434 |
|
| 2022 |
Maus MV. A decade of CAR T cell evolution. Nature Cancer. 3: 270-271. PMID 35288717 DOI: 10.1038/s43018-022-00347-4 |
0.522 |
|
| 2022 |
Gallagher KME, Leick MB, Larson RC, Berger TR, Katsis K, Yam JY, Maus MV. Differential T cell immunity to SARS-CoV-2 in mRNA-1273 and BNT162b2 vaccinated individuals. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 35278306 DOI: 10.1093/cid/ciac201 |
0.332 |
|
| 2022 |
How J, Gallagher KME, Liu Y, Katsis K, Elder EL, Larson RC, Leick MB, Neuberg D, Maus MV, Hobbs GS. Antibody and T-cell responses to SARS-CoV-2 vaccination in myeloproliferative neoplasm patients. Leukemia. PMID 35217807 DOI: 10.1038/s41375-022-01533-0 |
0.361 |
|
| 2022 |
Frigault MJ, Dietrich J, Gallagher KME, Roschewski MJ, Jordan JT, Forst D, Plotkin SR, Cook D, Casey KS, Lindell KA, DePinho GD, Katsis K, Elder EL, Leick M, Choi BD, ... ... Maus MV, et al. Safety and Efficacy of Tisagenlecleucel in Primary CNS Lymphoma: A phase I/II clinical trial. Blood. PMID 35167655 DOI: 10.1182/blood.2021014738 |
0.394 |
|
| 2022 |
Haydu JE, Maron JS, Redd RA, Gallagher KME, Fischinger S, Barnes JA, Hochberg EP, Johnson PC, Takvorian RW, Katsis K, Portman D, Ruiters J, Sechio S, Devlin MC, Regan C, ... ... Maus MV, et al. Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study. Blood Advances. PMID 35073571 DOI: 10.1182/bloodadvances.2021006627 |
0.316 |
|
| 2022 |
Wehrli M, Gallagher K, Chen YB, Leick MB, McAfee SL, El-Jawahri AR, DeFilipp Z, Horick N, O'Donnell P, Spitzer T, Dey B, Cook D, Trailor M, Lindell K, Maus MV, et al. Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS). Journal For Immunotherapy of Cancer. 10. PMID 34996813 DOI: 10.1136/jitc-2021-003847 |
0.384 |
|
| 2021 |
Bailey SR, Vatsa S, Larson RC, Bouffard AA, Scarfo I, Kann MC, Berger TR, Leick MB, Wehrli M, Schmidts A, Silva H, Lindell KA, Demato A, Gallagher KM, Frigault MJ, ... Maus MV, et al. Blockade or deletion of IFNg reduces macrophage activation without compromising CAR-T function in hematologic malignancies. Blood Cancer Discovery. PMID 35015685 DOI: 10.1158/2643-3230.BCD-21-0181 |
0.515 |
|
| 2021 |
Villalba JA, Maus MV, Frigault MJ, Zaffini R, Gandhi RT, Rosenberg ES, Siedner MJ. False-positive HIV testing in patients receiving lentivirus-based chimeric antigen receptor T-cell therapy: A case report, review of the literature and proposed recommendations. The Journal of Infectious Diseases. PMID 34927686 DOI: 10.1093/infdis/jiab605 |
0.357 |
|
| 2021 |
Yan C, Yang Q, Zhang S, Millar DG, Alpert EJ, Do D, Veloso A, Brunson DC, Drapkin BJ, Stanzione M, Scarfò I, Moore JC, Iyer S, Qin Q, Wei Y, ... ... Maus MV, et al. Single-cell imaging of T cell immunotherapy responses in vivo. The Journal of Experimental Medicine. 218. PMID 34415995 DOI: 10.1084/jem.20210314 |
0.572 |
|
| 2021 |
Kong W, Dimitri A, Wang W, Jung IY, Ott CJ, Fasolino M, Wang Y, Kulikovskaya I, Gupta M, Yoder T, DeNizio JE, Everett JK, Williams EF, Xu J, Scholler J, ... ... Maus MV, et al. BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia. The Journal of Clinical Investigation. 131. PMID 34396987 DOI: 10.1172/JCI145459 |
0.687 |
|
| 2021 |
Miller PG, Sperling AS, Brea EJ, Leick MB, Fell GG, Jan M, Gohil SH, Tai YT, Munshi NC, Wu CJ, Neuberg DS, Maus MV, Jacobson C, Gibson CJ, Ebert BL. Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. Blood Advances. 5: 2982-2986. PMID 34342642 DOI: 10.1182/bloodadvances.2021004554 |
0.478 |
|
| 2021 |
Wehrli M, Maus MV. New CARs on and off the road: challenges and new developments in CAR-T cell therapy. Current Opinion in Pharmacology. 59: 116-126. PMID 34198161 DOI: 10.1016/j.coph.2021.05.005 |
0.527 |
|
| 2021 |
Wehrli M, Maus MV. New CARs on and off the road: challenges and new developments in CAR-T cell therapy. Current Opinion in Pharmacology. 59: 116-126. PMID 34198161 DOI: 10.1016/j.coph.2021.05.005 |
0.527 |
|
| 2021 |
Weingarten-Gabbay S, Klaeger S, Sarkizova S, Pearlman LR, Chen DY, Gallagher KME, Bauer MR, Taylor HB, Dunn WA, Tarr C, Sidney J, Rachimi S, Conway HL, Katsis K, Wang Y, ... ... Maus MV, et al. Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs. Cell. PMID 34171305 DOI: 10.1016/j.cell.2021.05.046 |
0.332 |
|
| 2021 |
Maus MV. CD19 CAR T cells for adults with relapsed or refractory acute lymphoblastic leukaemia. Lancet (London, England). PMID 34097851 DOI: 10.1016/S0140-6736(21)01289-7 |
0.435 |
|
| 2021 |
Durgin JS, Henderson F, Nasrallah MP, Mohan S, Wang S, Lacey SF, Melenhorst JJ, Desai AS, Lee JYK, Maus MV, June CH, Brem S, O'Connor RS, Binder Z, O'Rourke DM. Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma. Frontiers in Oncology. 11: 669071. PMID 34026647 DOI: 10.3389/fonc.2021.669071 |
0.626 |
|
| 2021 |
Bai Z, Lundh S, Kim D, Woodhouse S, Barrett DM, Myers RM, Grupp SA, Maus MV, June CH, Camara PG, Melenhorst JJ, Fan R. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells. Journal For Immunotherapy of Cancer. 9. PMID 34006631 DOI: 10.1136/jitc-2020-002328 |
0.691 |
|
| 2021 |
Gallagher KME, Leick MB, Larson RC, Berger TR, Katsis K, Yam JY, Brini G, Grauwet K, Maus MV. SARS -CoV-2 T-cell immunity to variants of concern following vaccination. Biorxiv : the Preprint Server For Biology. PMID 33972942 DOI: 10.1101/2021.05.03.442455 |
0.367 |
|
| 2021 |
Johansson U, Gallagher K, Burgoyne V, Maus MV, Casey KS, Brini GG, Frigault MJ, Yam JY, Chavda N, Besley C, Lugthart S. Detection of CAR-T19 cells in peripheral blood and cerebrospinal fluid: An assay applicable to routine diagnostic laboratories. Cytometry. Part B, Clinical Cytometry. PMID 33915021 DOI: 10.1002/cyto.b.22005 |
0.517 |
|
| 2021 |
Yu X, Curry WT, Gerstner ER, Cahill DP, Nahed BV, Maus MV, Carter BS, Choi BD. Commentary: Chimeric Antigen Receptor T-Cell Therapy: Updates in Glioblastoma Treatment. Neurosurgery. PMID 33826726 DOI: 10.1093/neuros/nyab099 |
0.493 |
|
| 2021 |
Berger TR, Maus MV. Mechanisms of response and resistance to CAR T cell therapies. Current Opinion in Immunology. 69: 56-64. PMID 33752101 DOI: 10.1016/j.coi.2021.02.010 |
0.595 |
|
| 2021 |
Clayton KL, Mylvaganam G, Villasmil-Ocando A, Stuart H, Maus MV, Rashidian M, Ploegh HL, Walker BD. HIV-infected macrophages resist efficient NK cell-mediated killing while preserving inflammatory cytokine responses. Cell Host & Microbe. PMID 33571449 DOI: 10.1016/j.chom.2021.01.006 |
0.309 |
|
| 2021 |
Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nature Reviews. Cancer. PMID 33483715 DOI: 10.1038/s41568-020-00323-z |
0.52 |
|
| 2021 |
Jan M, Scarfò I, Larson RC, Walker A, Schmidts A, Guirguis AA, Gasser JA, Słabicki M, Bouffard AA, Castano AP, Kann MC, Cabral ML, Tepper A, Grinshpun DE, Sperling AS, ... ... Maus MV, et al. Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide. Science Translational Medicine. 13. PMID 33408186 DOI: 10.1126/scitranslmed.abb6295 |
0.414 |
|
| 2020 |
Maus MV, Alexander S, Bishop MR, Brudno JN, Callahan C, Davila ML, Diamonte C, Dietrich J, Fitzgerald JC, Frigault MJ, Fry TJ, Holter-Chakrabarty JL, Komanduri KV, Lee DW, Locke FL, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. Journal For Immunotherapy of Cancer. 8. PMID 33335028 DOI: 10.1136/jitc-2020-001511 |
0.386 |
|
| 2020 |
Benjamin R, Graham C, Yallop D, Jozwik A, Mirci-Danicar OC, Lucchini G, Pinner D, Jain N, Kantarjian H, Boissel N, Maus MV, Frigault MJ, Baruchel A, Mohty M, Gianella-Borradori A, et al. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet (London, England). 396: 1885-1894. PMID 33308471 DOI: 10.1016/S0140-6736(20)32334-5 |
0.458 |
|
| 2020 |
Jacobson CA, Maus MV. C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas. Blood Advances. 4: 5858-5862. PMID 33232481 DOI: 10.1182/bloodadvances.2020003391 |
0.52 |
|
| 2020 |
Leick MB, Maus MV, Frigault MJ. Clinical Perspective: Treatment of Aggressive B Cell Lymphomas with FDA-Approved CAR-T Cell Therapies. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 33130313 DOI: 10.1016/j.ymthe.2020.10.022 |
0.472 |
|
| 2020 |
Schmidts A, Marsh LC, Srivastava AA, Bouffard AA, Boroughs AC, Scarfò I, Larson RC, Bedoya F, Choi BD, Frigault MJ, Bailey SR, Leick MB, Vatsa S, Kann MC, Prew MS, ... ... Maus MV, et al. Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources. Journal For Immunotherapy of Cancer. 8. PMID 32900862 DOI: 10.1136/Jitc-2020-000990 |
0.638 |
|
| 2020 |
Schmidts A, Wehrli M, Maus MV. Toward Better Understanding and Management of CAR-T Cell-Associated Toxicity. Annual Review of Medicine. PMID 32776808 DOI: 10.1146/Annurev-Med-061119-015600 |
0.613 |
|
| 2020 |
Boroughs AC, Larson RC, Marjanovic ND, Gosik K, Castano AP, Porter CBM, Lorrey SJ, Ashenberg O, Jerby L, Hofree M, Smith-Rosario G, Morris R, Gould J, Riley LS, Berger TR, ... ... Maus MV, et al. A Distinct Transcriptional Program in Human CAR T Cells Bearing the 4-1BB Signaling Domain Revealed by scRNA-Seq. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 32755564 DOI: 10.1016/J.Ymthe.2020.07.023 |
0.594 |
|
| 2020 |
Jacobson CA, Hunter BD, Redd R, Rodig SJ, Chen PH, Wright K, Lipschitz M, Ritz J, Kamihara Y, Armand P, Nikiforow S, Rogalski M, Maakaron J, Jaglowski S, Maus MV, et al. Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1902103. PMID 32667831 DOI: 10.1200/Jco.19.02103 |
0.306 |
|
| 2020 |
Dunn GP, Cloughesy TF, Maus MV, Prins RM, Reardon DA, Sonabend AM. Emerging Immunotherapies for Malignant Glioma: From Immunogenomics to Cell Therapy. Neuro-Oncology. PMID 32615600 DOI: 10.1093/neuonc/noaa154 |
0.335 |
|
| 2020 |
Gutierrez C, Brown ART, Herr MM, Kadri SS, Hill B, Rajendram P, Duggal A, Turtle CJ, Patel K, Lin Y, May HP, Gallo de Moraes A, Maus MV, Frigault MJ, Brudno JN, et al. The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities. Journal of Critical Care. 58: 58-64. PMID 32361219 DOI: 10.1016/J.Jcrc.2020.04.008 |
0.4 |
|
| 2020 |
Maryamchik E, Gallagher KME, Preffer FI, Kadauke S, Maus MV. New directions in chimeric antigen receptor T cell [CAR-T] therapy and related flow cytometry. Cytometry. Part B, Clinical Cytometry. PMID 32352629 DOI: 10.1002/Cyto.B.21880 |
0.598 |
|
| 2020 |
Weber EW, Maus MV, Mackall CL. The Emerging Landscape of Immune Cell Therapies. Cell. 181: 46-62. PMID 32243795 DOI: 10.1016/J.Cell.2020.03.001 |
0.428 |
|
| 2020 |
Frigault MJ, Maus MV. State of the art in CAR T cell therapy for CD19+ B cell malignancies. The Journal of Clinical Investigation. 130: 1586-1594. PMID 32235098 DOI: 10.1172/Jci129208 |
0.643 |
|
| 2020 |
Scarfò I, Maus MV. Unraveling the Signaling Balance of Activation and Exhaustion of CAR T Cells. Cancer Cell. 37: 143-144. PMID 32049043 DOI: 10.1016/J.Ccell.2020.01.006 |
0.513 |
|
| 2020 |
Nardi V, Ku N, Frigault MJ, Dubuc AM, Tsai HK, Amrein PC, Hobbs GS, Brunner AM, Narayan R, Burke ME, Foster J, Dal Cin P, Maus MV, Fathi AT, Hock H. Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangement. Blood Advances. 4: 106-111. PMID 31905241 DOI: 10.1182/Bloodadvances.2019000769 |
0.404 |
|
| 2019 |
Wang X, Scarfò I, Schmidts A, Toner M, Maus MV, Irimia D. Dynamic Profiling of Antitumor Activity of CAR T Cells Using Micropatterned Tumor Arrays. Advanced Science (Weinheim, Baden-Wurttemberg, Germany). 6: 1901829. PMID 31832320 DOI: 10.1002/Advs.201901829 |
0.629 |
|
| 2019 |
Choi BD, Yu X, Castano AP, Darr H, Henderson DB, Bouffard AA, Larson RC, Scarfò I, Bailey SR, Gerhard GM, Frigault MJ, Leick MB, Schmidts A, Sagert JG, Curry WT, ... ... Maus MV, et al. CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma. Journal For Immunotherapy of Cancer. 7: 304. PMID 31727131 DOI: 10.1186/S40425-019-0806-7 |
0.567 |
|
| 2019 |
Schmidts A, Ormhøj M, Choi BD, Taylor AO, Bouffard AA, Scarfò I, Larson RC, Frigault MJ, Gallagher K, Castano AP, Riley LS, Cabral ML, Boroughs AC, Velasco Cárdenas RM, Schamel W, ... ... Maus MV, et al. Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. Blood Advances. 3: 3248-3260. PMID 31698455 DOI: 10.1182/Bloodadvances.2019000703 |
0.485 |
|
| 2019 |
Mondal N, Silva M, Castano AP, Maus MV, Sackstein R. Glycoengineering of Chimeric Antigen Receptor (CAR) T-cells to Enforce E-selectin Binding. The Journal of Biological Chemistry. PMID 31628196 DOI: 10.1074/Jbc.Ra119.011134 |
0.583 |
|
| 2019 |
Mylvaganam G, Yanez AG, Maus M, Walker BD. Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology. Frontiers in Immunology. 10: 2109. PMID 31552045 DOI: 10.3389/Fimmu.2019.02109 |
0.555 |
|
| 2019 |
Ormhøj M, Scarfò I, Cabral ML, Bailey SR, Lorrey SJ, Bouffard AA, Castano AP, Larson RC, Riley LS, Schmidts A, Choi BD, Andersen RS, Cédile O, Nyvold CG, Haaber J, ... ... Maus MV, et al. Chimeric antigen receptor T cells targeting CD79b show efficacy in lymphoma with or without co-targeting CD19. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31439577 DOI: 10.1158/1078-0432.Ccr-19-1337 |
0.631 |
|
| 2019 |
Choi BD, Yu X, Castano AP, Bouffard AA, Schmidts A, Larson RC, Bailey SR, Boroughs AC, Frigault MJ, Leick MB, Scarfò I, Cetrulo CL, Demehri S, Nahed BV, Cahill DP, ... ... Maus MV, et al. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nature Biotechnology. PMID 31332324 DOI: 10.1038/S41587-019-0192-1 |
0.631 |
|
| 2019 |
Frigault MJ, Dietrich J, Martinez-Lage M, Leick M, Choi BD, DeFilipp Z, Chen YB, Abramson J, Crombie J, Armand P, Nayak L, Panzini C, Riley LS, Gallagher K, Maus M. Tisagenlecleucel CAR-T Cell Therapy in Secondary CNS Lymphoma. Blood. PMID 31320380 DOI: 10.1182/Blood.2019001694 |
0.639 |
|
| 2019 |
Li M, Chin LY, Shukor S, Tamayo AG, Maus MV, Parekkadan B. Effects of intermittent T-cell cluster disaggregation on proliferative capacity and checkpoint marker expression. Autoimmunity. 1-6. PMID 31238751 DOI: 10.1080/08916934.2019.1630064 |
0.566 |
|
| 2019 |
Bailey SR, Maus MV. Gene editing for immune cell therapies. Nature Biotechnology. PMID 31160723 DOI: 10.1038/S41587-019-0137-8 |
0.583 |
|
| 2019 |
Baeuerle PA, Ding J, Patel E, Thorausch N, Horton H, Gierut J, Scarfo I, Choudhary R, Kiner O, Krishnamurthy J, Le B, Morath A, Baldeviano GC, Quinn J, Tavares P, ... ... Maus MV, et al. Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response. Nature Communications. 10: 2087. PMID 31064990 DOI: 10.1038/S41467-019-10097-0 |
0.651 |
|
| 2019 |
Scarfò I, Frigault MJ, Maus MV. CAR-Based Approaches to Cutaneous T-Cell Lymphoma. Frontiers in Oncology. 9: 259. PMID 31058076 DOI: 10.3389/Fonc.2019.00259 |
0.644 |
|
| 2019 |
Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang J, et al. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. The New England Journal of Medicine. 380: 1726-1737. PMID 31042825 DOI: 10.1056/Nejmoa1817226 |
0.625 |
|
| 2019 |
Leick M, Maus MV. Wishing on a CAR: Understanding the Scope of Intrinsic T-cell Deficits in Patients with Cancer. Cancer Discovery. 9: 466-468. PMID 30936218 DOI: 10.1158/2159-8290.Cd-19-0073 |
0.564 |
|
| 2019 |
Boroughs AC, Larson RC, Choi BD, Bouffard AA, Riley LS, Schiferle E, Kulkarni AS, Cetrulo CL, Ting D, Blazar BR, Demehri S, Maus MV. Chimeric antigen receptor costimulation domains modulate human regulatory T cell function. Jci Insight. 5. PMID 30869654 DOI: 10.1172/Jci.Insight.126194 |
0.565 |
|
| 2019 |
Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, ... ... Maus MV, et al. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. Jci Insight. 4. PMID 30830874 DOI: 10.1172/jci.insight.127684 |
0.565 |
|
| 2019 |
Karschnia P, Jordan JT, Forst DA, Arrillaga-Romany IC, Batchelor TT, Baehring JM, Clement NF, Gonzalez Castro LN, Herlopian A, Maus MV, Schwaiblmair MH, Soumerai JD, Takvorian RW, Hochberg EP, Barnes JA, et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T-cells. Blood. PMID 30808634 DOI: 10.1182/Blood-2018-12-893396 |
0.573 |
|
| 2019 |
Kleinstiver BP, Sousa AA, Walton RT, Tak YE, Hsu JY, Clement K, Welch MM, Horng JE, Malagon-Lopez J, Scarfò I, Maus MV, Pinello L, Aryee MJ, Joung JK. Engineered CRISPR-Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing. Nature Biotechnology. PMID 30742127 DOI: 10.1038/S41587-018-0011-0 |
0.376 |
|
| 2019 |
Guedan S, Calderon H, Posey AD, Maus MV. Engineering and Design of Chimeric Antigen Receptors. Molecular Therapy. Methods & Clinical Development. 12: 145-156. PMID 30666307 DOI: 10.1016/J.Omtm.2018.12.009 |
0.532 |
|
| 2019 |
Leick MB, Maus MV. CAR-T cells beyond CD19, UnCAR-Ted territory. American Journal of Hematology. PMID 30632631 DOI: 10.1002/Ajh.25398 |
0.592 |
|
| 2019 |
Fathi A, Ebert B, Motamedi M, Parikh AR, Drapkin B, Lin JJ, Saladi SV, Maus M. 10th Chabner Colloquium: Answering the Big Questions in Cancer ResearchAbstract 1 – IDH Inhibition in Acute Myeloid Leukemia: Emergence of a New Therapeutic EraAbstract 2 – Clonal HematopoiesisAbstract 3 – Epigenetic Reversal of Chemotherapy Resistance in CancersAbstract 4 – ctDNA, a Biomarker of Residual Disease and Tumor Response in Gastrointestinal CancersAbstract 5 – Cross‐Resistance in Small Cell Lung CancerAbstract 6 – RET as a Target in Lung CancerAbstract 7 – Targeting SWI/SNF‐Hippo Axis in Squamous CancersAbstract 8 – Innovations in Cell Therapy The Oncologist. 24: S1-S4. DOI: 10.1634/Theoncologist.2019-Ma-1 |
0.349 |
|
| 2019 |
Scarfò I, Gallagher K, Maus MV, Larson R, Sheehan M, Brini G, Bornheimer S, Hanley MB, Frigault M, Leick M, Chekmasova A. Application of a Standardized Flow Cytometry Panel for Defining and Monitoring the Immunophenotype of CAR-T Cells Blood. 134: 5626-5626. DOI: 10.1182/Blood-2019-128745 |
0.603 |
|
| 2019 |
Leick M, Scarfò I, Choi BD, Larson R, Bouffard AA, Castano A, Cabral ML, Schmidts A, Frigault MJ, Maus MV. Use of CD70 Targeted Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Acute Myeloid Leukemia (AML) Blood. 134: 4443-4443. DOI: 10.1182/Blood-2019-127154 |
0.607 |
|
| 2019 |
Jan M, Castano A, Walker A, Guirguis AA, Gasser JA, Bouffard AA, Slabicki M, Tepper A, Grinshpun DE, Kyung T, Sievers Q, Birnbaum ME, Maus MV, Ebert BL. Exploiting the Zinc Finger Degrome Targeted By Lenalidomide to Engineer Reversible Off-Switch Degradable Chimeric Antigen Receptors Blood. 134: 866-866. DOI: 10.1182/Blood-2019-124210 |
0.567 |
|
| 2019 |
Choi BD, Yu X, Castano AP, Bouffard AA, Curry WT, Carter BS, Maus MV. Abstract LB-066: BiTE-armored CARs overcome antigen escape in EGFRvIII-targeted therapy for glioblastoma Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-066 |
0.642 |
|
| 2019 |
Horton H, Ding J, Shah S, Gierut J, Thorausch N, Morath A, Shamel W, Maus M, Baeuerle P, Hofmeister R, Getts DR. Abstract 2330: Preclinical evaluation of TC-110: CD19-specific T cell receptor (TCR) fusion construct (TRuC™) T cell for the treatment of hematologic malignancies Cancer Research. 79: 2330-2330. DOI: 10.1158/1538-7445.Am2019-2330 |
0.679 |
|
| 2019 |
Choi BD, Yu X, Castano AP, Bouffard AA, Schmidts A, Larson RC, Bailey SR, Boroughs AC, Frigault MJ, Leick MB, Scarfo I, Cetrulo CL, Demehri S, Nahed BV, Cahill DP, ... ... Maus MV, et al. Bispecific T-Cell Engager -Armored Chimeric Antigen Receptor T Cells Overcome Antigen Escape From EGFRvIII-Targeted Therapy For Glioblastoma Neurosurgery. 66. DOI: 10.1093/Neuros/Nyz310_154 |
0.648 |
|
| 2018 |
Aijaz A, Li M, Smith D, Khong D, LeBlon C, Fenton OS, Olabisi RM, Libutti S, Tischfield J, Maus MV, Deans R, Barcia RN, Anderson DG, Ritz J, Preti R, et al. Biomanufacturing for clinically advanced cell therapies. Nature Biomedical Engineering. 2: 362-376. PMID 31011198 DOI: 10.1038/S41551-018-0246-6 |
0.515 |
|
| 2018 |
Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, Go WY, Eldjerou L, Gardner RA, Frey N, Curran KJ, et al. ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 30592986 DOI: 10.1016/J.Bbmt.2018.12.758 |
0.538 |
|
| 2018 |
Fishman JA, Hogan JI, Maus MV. Inflammatory and Infectious Syndromes Associated with Cancer Immunotherapies. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 30520987 DOI: 10.1093/Cid/Ciy1025 |
0.485 |
|
| 2018 |
Boyiadzis MM, Dhodapkar MV, Brentjens RJ, Kochenderfer JN, Neelapu SS, Maus MV, Porter DL, Maloney DG, Grupp SA, Mackall CL, June CH, Bishop MR. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. Journal For Immunotherapy of Cancer. 6: 137. PMID 30514386 DOI: 10.1186/S40425-018-0460-5 |
0.668 |
|
| 2018 |
Li M, Chin LY, Shukor S, Tamayo A, Maus MV, Parekkadan B. Closed loop bioreactor system for the ex vivo expansion of human T cells. Cytotherapy. PMID 30497956 DOI: 10.1016/J.Jcyt.2018.10.009 |
0.453 |
|
| 2018 |
Schmidts A, Maus MV. Making CAR T Cells a Solid Option for Solid Tumors. Frontiers in Immunology. 9: 2593. PMID 30467505 DOI: 10.3389/Fimmu.2018.02593 |
0.642 |
|
| 2018 |
Choi BD, Maus MV, June CH, Sampson JH. ----Immunotherapy for Glioblastoma: Adoptive T-cell Strategies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30446589 DOI: 10.1158/1078-0432.Ccr-18-1625 |
0.716 |
|
| 2018 |
Scarfò I, Ormhøj M, Frigault MJ, Castano AP, Lorrey S, Bouffard AA, van Scoyk A, Rodig SJ, Shay AJ, Aster JC, Preffer FI, Weinstock DM, Maus MV. Anti-CD37 chimeric antigen receptor T cells are active against B and T cell lymphomas. Blood. PMID 30089630 DOI: 10.1182/Blood-2018-04-842708 |
0.642 |
|
| 2018 |
Tang L, Zheng Y, Melo MB, Mabardi L, Castaño AP, Xie YQ, Li N, Kudchodkar SB, Wong HC, Jeng EK, Maus MV, Irvine DJ. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. Nature Biotechnology. PMID 29985479 DOI: 10.1038/Nbt.4181 |
0.64 |
|
| 2018 |
Leick MB, Maus MV. Toxicities associated with immunotherapies for hematologic malignancies. Best Practice & Research. Clinical Haematology. 31: 158-165. PMID 29909916 DOI: 10.1016/J.Beha.2018.03.004 |
0.621 |
|
| 2018 |
Maus MV. Tumour tamed by transfer of one T cell. Nature. 558: 193-195. PMID 29895908 DOI: 10.1038/D41586-018-05251-5 |
0.529 |
|
| 2018 |
Choi BD, Curry WT, Carter BS, Maus MV. Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons. Neurosurgical Focus. 44: E13. PMID 29852773 DOI: 10.3171/2018.2.Focus17788 |
0.591 |
|
| 2018 |
Kloss CC, Lee J, Zhang A, Chen F, Melenhorst JJ, Lacey SF, Maus MV, Fraietta JA, Zhao Y, June CH. Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 29807781 DOI: 10.1016/J.Ymthe.2018.05.003 |
0.566 |
|
| 2018 |
Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, ... ... Maus MV, et al. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. Jci Insight. 3. PMID 29669947 DOI: 10.1172/Jci.Insight.120505 |
0.681 |
|
| 2018 |
Berdeja JG, Lin Y, Kochenderfer J, Raje NS, Munshi NC, Siegel DSD, Liedtke M, Madduri D, Rosenblatt J, Maus MV, Turka A, Lam LP, Hege K, Campbell TB, Massaro M, et al. Association of high baseline ferritin with tocilizumab administration for CRS in relapsed/refractory multiple myeloma patients treated with bb2121 anti-BCMA CAR T cells. Journal of Clinical Oncology. 36: e15062-e15062. DOI: 10.1200/Jco.2018.36.15_Suppl.E15062 |
0.523 |
|
| 2018 |
Munshi NC, Berdeja JG, Lin Y, Kochenderfer J, Raje NS, Liedtke M, Jagannath S, Madduri D, Rosenblatt J, Maus MV, Turka A, Lam LP, Hege K, Campbell TB, Massaro M, et al. Early MRD negativity to predict deepening myeloma response in relapsed/refractory multiple myeloma (RRMM) patients treated with bb2121 anti-BCMA CAR T cells. Journal of Clinical Oncology. 36: 8024-8024. DOI: 10.1200/Jco.2018.36.15_Suppl.8024 |
0.528 |
|
| 2018 |
Raje NS, Berdeja JG, Lin Y, Munshi NC, Siegel DSD, Liedtke M, Jagannath S, Madduri D, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Quigley T, Massaro M, et al. bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study. Journal of Clinical Oncology. 36: 8007-8007. DOI: 10.1200/Jco.2018.36.15_Suppl.8007 |
0.647 |
|
| 2018 |
Schmidts A, Ormhoj M, Taylor AO, Lorrey SJ, Scarfò I, Frigault MJ, Choi BD, Maus MV. Engineering an Optimized Trimeric APRIL-Based CAR to Broaden Targetability of Multiple Myeloma Blood. 132: 2059-2059. DOI: 10.1182/Blood-2018-99-119633 |
0.612 |
|
| 2018 |
Mondal N, Silva M, Castano A, Maus MV, Sackstein R. Overcoming a Critical Obstacle Towards Effective and Safe CAR T-Cell Therapeutics Blood. 132: 2056-2056. DOI: 10.1182/Blood-2018-99-118675 |
0.636 |
|
| 2018 |
Jacobson CA, Hunter B, Armand P, Kamihara Y, Ritz J, Rodig SJ, Wright K, Lipschitz M, Redd RA, Maus MV, Chen Y, Abramson JS, Kline J, Cohen JB, Maakaron J, et al. Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity Blood. 132: 92-92. DOI: 10.1182/Blood-2018-99-117199 |
0.405 |
|
| 2018 |
Maus M. Abstract IA19: New directions in T cell therapies for cancer Cancer Immunology Research. 6. DOI: 10.1158/2326-6074.Tumimm17-Ia19 |
0.611 |
|
| 2018 |
Patel E, Ding J, Thorausch N, Krishnamurthy J, Choudhary R, Weiler S, Le B, Tavares P, Zieba A, Quinn J, Wang Y, Schamel W, Scarfo I, Maus M, Baeuerle P, et al. Abstract 3584: Characterization of a novel class of engineered (TCR) fusion constructs (TRuCTMs) aimed to treat solid tumors Cancer Research. 78: 3584-3584. DOI: 10.1158/1538-7445.Am2018-3584 |
0.64 |
|
| 2017 |
Choi BD, O'Rourke DM, Maus MV. Engineering Chimeric Antigen Receptor T cells to Treat Glioblastoma. The Journal of Targeted Therapies in Cancer. 6: 22-25. PMID 29167820 |
0.576 |
|
| 2017 |
O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, Isaacs R, Mohan S, Plesa G, Lacey SF, Navenot JM, ... ... Maus MV, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Science Translational Medicine. 9. PMID 28724573 DOI: 10.1126/Scitranslmed.Aaa0984 |
0.677 |
|
| 2017 |
Long M, Beckwith K, Do P, Mundy BL, Gordon A, Lehman AM, Maddocks KJ, Cheney C, Jones JA, Flynn JM, Andritsos LA, Awan F, Fraietta JA, June CH, Maus MV, et al. Ibrutinib treatment improves T cell number and function in CLL patients. The Journal of Clinical Investigation. PMID 28714866 DOI: 10.1172/Jci89756 |
0.578 |
|
| 2017 |
Sampson JH, Maus MV, June CH. Immunotherapy for Brain Tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017728089. PMID 28640704 DOI: 10.1200/Jco.2017.72.8089 |
0.457 |
|
| 2017 |
Maus MV, Nikiforow S. The Why, what, and How of the New FACT standards for immune effector cells. Journal For Immunotherapy of Cancer. 5: 36. PMID 28428885 DOI: 10.1186/S40425-017-0239-0 |
0.528 |
|
| 2017 |
Scarfò I, Maus MV. Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment. Journal For Immunotherapy of Cancer. 5: 28. PMID 28331617 DOI: 10.1186/S40425-017-0230-9 |
0.57 |
|
| 2017 |
Tanyi JL, Stashwick C, Plesa G, Morgan MA, Porter D, Maus MV, June CH. Possible Compartmental Cytokine Release Syndrome in a Patient With Recurrent Ovarian Cancer After Treatment With Mesothelin-targeted CAR-T Cells. Journal of Immunotherapy (Hagerstown, Md. : 1997). PMID 28234665 DOI: 10.1097/Cji.0000000000000160 |
0.697 |
|
| 2017 |
Ormhøj M, Bedoya F, Frigault MJ, Maus MV. CARs in the Lead Against Multiple Myeloma. Current Hematologic Malignancy Reports. PMID 28233151 DOI: 10.1007/S11899-017-0373-2 |
0.65 |
|
| 2017 |
Maus MV. Immunology: T-cell tweaks to target tumours. Nature. PMID 28225762 DOI: 10.1038/Nature21506 |
0.645 |
|
| 2017 |
Bedoya F, Frigault MJ, Maus MV. The Flipside of the Power of Engineered T Cells: Observed and Potential Toxicities of Genetically Modified T Cells as Therapy. Molecular Therapy : the Journal of the American Society of Gene Therapy. 25: 314-320. PMID 28153085 DOI: 10.1016/J.Ymthe.2016.11.011 |
0.586 |
|
| 2017 |
Berdeja JG, Lin Y, Raje NS, Siegel DSD, Munshi NC, Liedtke M, Jagannath S, Maus MV, Turka A, Lam LP, Hege K, Morgan R, Quigley MT, Kochenderfer J. First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: Updated results. Journal of Clinical Oncology. 35: 3010-3010. DOI: 10.1200/Jco.2017.35.15_Suppl.3010 |
0.579 |
|
| 2017 |
Berdeja JG, Lin Y, Raje N, Munshi N, Siegel D, Liedtke M, Jagannath S, Maus MV, Turka A, Lam LP, Hege K, Morgan RA, Quigley MT, Kochenderfer JN. Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy Blood. 130: 740-740. DOI: 10.1182/Blood.V130.Suppl_1.740.740 |
0.581 |
|
| 2017 |
Castano A, Tang L, Kudchodkar S, Darrell I, Maus M. Abstract B59: Enhancing T-cell therapy through TCR signaling-responsive nanogel drug delivery Cancer Immunology Research. 5. DOI: 10.1158/2326-6074.Tumimm16-B59 |
0.663 |
|
| 2017 |
Maus MV. Immunoengineering: Valet parking for CAR genes Nature Biomedical Engineering. 1. DOI: 10.1038/S41551-017-0085 |
0.447 |
|
| 2016 |
Maus MV, Plotkin J, Jakka G, Stewart-Jones G, Rivière I, Merghoub T, Wolchok J, Renner C, Sadelain M. An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity. Molecular Therapy Oncolytics. 3: 1-9. PMID 29675462 DOI: 10.1038/Mto.2016.23 |
0.541 |
|
| 2016 |
Ruella M, Maus MV. Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies. Computational and Structural Biotechnology Journal. 14: 357-362. PMID 27761200 DOI: 10.1016/J.Csbj.2016.09.003 |
0.602 |
|
| 2016 |
Maus MV, June CH. Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 22: 1875-84. PMID 27084741 DOI: 10.1158/1078-0432.Ccr-15-1433 |
0.757 |
|
| 2016 |
Fesnak A, Lin C, Siegel DL, Maus MV. CAR-T Cell Therapies From the Transfusion Medicine Perspective. Transfusion Medicine Reviews. PMID 27067907 DOI: 10.1016/J.Tmrv.2016.03.001 |
0.642 |
|
| 2016 |
Fraietta JA, Schwab RD, Maus MV. Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells. Seminars in Oncology. 43: 291-9. PMID 27040708 DOI: 10.1053/J.Seminoncol.2016.02.006 |
0.671 |
|
| 2016 |
Frigault MJ, Maus MV. Chimeric antigen receptor-modified T cells strike back. International Immunology. PMID 27021308 DOI: 10.1093/Intimm/Dxw018 |
0.664 |
|
| 2016 |
Maus MV, Levine BL. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist. The Oncologist. PMID 27009942 DOI: 10.1634/Theoncologist.2015-0421 |
0.648 |
|
| 2016 |
Zhukovsky EA, Morse RJ, Maus MV. Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection. Current Opinion in Immunology. 40: 24-35. PMID 26963133 DOI: 10.1016/J.Coi.2016.02.006 |
0.623 |
|
| 2016 |
Maus MV. Innate immune signaling in CLL. Blood. 127: 376-8. PMID 26823508 DOI: 10.1182/Blood-2015-11-679845 |
0.305 |
|
| 2016 |
Ruella M, Kenderian SS, Shestova O, Fraietta JA, Qayyum S, Zhang Q, Maus MV, Liu X, Nunez-Cruz S, Klichinsky M, Kawalekar OU, Lacey SF, Milone M, Mato AR, Schuster SJ, et al. The Addition of the BTK inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26819453 DOI: 10.1158/1078-0432.Ccr-15-1527 |
0.682 |
|
| 2016 |
Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM, Lacey SF, Melenhorst JJ, McGettigan SE, Cook DR, Zhang C, Xu J, Do P, Hulitt J, Kudchodkar SB, ... ... Maus MV, et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. PMID 26813675 DOI: 10.1182/Blood-2015-11-679134 |
0.748 |
|
| 2016 |
O'Rourke DM, Nasrallah M, Morrissette JJ, Melenhorst JJ, Lacey SF, Mansfield K, Martinez-Lage M, Desai AS, Brem S, Maloney E, Mohan S, Wang S, Verma G, Navenot J, Shen A, ... ... Maus MV, et al. Pilot study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma. Journal of Clinical Oncology. 34: 2067-2067. DOI: 10.1200/Jco.2016.34.15_Suppl.2067 |
0.643 |
|
| 2016 |
Garfall AL, Stadtmauer EA, Maus MV, Hwang W, Vogl DT, Cohen AD, Weiss BM, Porter DL, Frey N, Milone M, Mangan P, Krevvata M, Ayers E, Dengel K, Kerr ND, et al. Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CTL019) in Conjunction with Salvage Autologous Stem Cell Transplantation for Advanced Multiple Myeloma Blood. 128: 974-974. DOI: 10.1182/Blood.V128.22.974.974 |
0.595 |
|
| 2016 |
Jesuraj NJ, Cole JM, Bedoya F, Wells SB, Qin G, Kevlahan S, Maus MV, Ball AJ. A Novel Phase-Change Hydrogel Substrate for T Cell Activation Promotes Increased Expansion of CD8+ Cells Expressing Central Memory and Naive Phenotype Markers Blood. 128: 3368-3368. DOI: 10.1182/Blood.V128.22.3368.3368 |
0.527 |
|
| 2016 |
Long M, Beckwith KA, Do P, Bethany ML, Gordon G, Lehman AM, Maddocks KJ, Cheney C, Jones J, Andritsos LA, Awan FT, Fraietta JA, June CH, Maus MV, Woyach JA, et al. Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism Blood. 128: 3238-3238. DOI: 10.1182/Blood.V128.22.3238.3238 |
0.714 |
|
| 2016 |
Cogdill AP, Boesteanu A, Xu C, Haines K, Scholler J, Fraietta J, Zhao Y, Liu X, Morrissette J, Levine B, Lacey S, Loew A, Singh R, Brogdon J, O'Rourke DM, ... Maus MV, et al. Abstract B139: Toxicity testing of EGFRvIII CAR-based immunotherapy of glioblastoma: From bench to bedside Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-B139 |
0.714 |
|
| 2016 |
O’Rourke DM, Nasrallah MP, Morrissette J, Melenhorst JJ, Lacey SF, Mansfield K, Martinez-Lage M, Desai A, Brem S, Maloney E, Mohan S, Wang S, Verma G, Navenot J, Shen A, ... ... Maus MV, et al. Abstract LB-083: Phase I study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-083 |
0.703 |
|
| 2015 |
Miller BC, Maus MV. CD19-Targeted CAR T Cells: A New Tool in the Fight against B Cell Malignancies. Oncology Research and Treatment. 38: 683-90. PMID 26633875 DOI: 10.1159/000442170 |
0.658 |
|
| 2015 |
Maus MV, Powell DJ. Chimeric Antigen Receptor T-Cells: New Approaches to Improve Their Efficacy and Reduce Toxicity. Cancer Journal (Sudbury, Mass.). 21: 475-9. PMID 26588679 DOI: 10.1097/Ppo.0000000000000155 |
0.622 |
|
| 2015 |
Maus MV. Designing CAR T cells for glioblastoma. Oncoimmunology. 4: e1048956. PMID 26587317 DOI: 10.1080/2162402X.2015.1048956 |
0.595 |
|
| 2015 |
Gill S, Maus MV, Porter DL. Chimeric antigen receptor T cell therapy: 25years in the making. Blood Reviews. PMID 26574053 DOI: 10.1016/J.Blre.2015.10.003 |
0.612 |
|
| 2015 |
Garfall AL, Maus MV, Hwang WT, Lacey SF, Mahnke YD, Melenhorst JJ, Zheng Z, Vogl DT, Cohen AD, Weiss BM, Dengel K, Kerr ND, Bagg A, Levine BL, June CH, et al. Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. The New England Journal of Medicine. 373: 1040-7. PMID 26352815 DOI: 10.1056/Nejmoa1504542 |
0.655 |
|
| 2015 |
Johnson LA, Scholler J, Ohkuri T, Kosaka A, Patel PR, McGettigan SE, Nace AK, Dentchev T, Thekkat P, Loew A, Boesteanu AC, Cogdill AP, Chen T, Fraietta JA, Kloss CC, ... ... Maus MV, et al. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Science Translational Medicine. 7: 275ra22. PMID 25696001 DOI: 10.1126/Scitranslmed.Aaa4963 |
0.698 |
|
| 2015 |
Garfall AL, Maus MV, Lacey SF, Mahnke YD, Melenhorst JJ, Zheng Z, Vogl DT, Cohen AD, Weiss BM, Dengel K, Kerr ND, Hwang W, Levine B, June CH, Stadtmauer EA. Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR)-modified autologous T cells (CTL019) in advanced multiple myeloma. Journal of Clinical Oncology. 33: 8517-8517. DOI: 10.1200/Jco.2015.33.15_Suppl.8517 |
0.616 |
|
| 2015 |
Ruella M, Kenderian SS, Shestova O, Fraietta JA, Qayyum S, Zhang Q, Maus MV, Liu X, Nunez-Cruz S, Klichinsky M, Kawalekar OU, Milone MC, Lacey SF, Mato A, Schuster SJ, et al. The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Engraftment and Antitumor Responses Against Mantle Cell Lymphoma Blood. 126: 704-704. DOI: 10.1182/Blood.V126.23.704.704 |
0.605 |
|
| 2015 |
Cogdill AP, Boesteanu A, Haines K, Fraietta J, Scholler J, Loew A, Thekkat P, Brogdon J, Maus MV, June C, Johnson LA. Abstract B05: A biologic screen to evaluate potential toxicity of chimeric antigen receptor modified T cells against primary normal human tissues Cancer Immunology Research. 3. DOI: 10.1158/2326-6074.Tumimm14-B05 |
0.697 |
|
| 2015 |
Tanyi JL, Haas AR, Beatty GL, Morgan MA, Stashwick CJ, O'Hara MH, Porter DL, Maus MV, Levine BL, Lacey SF, Nelson AM, McGarvey M, Kerr ND, Plesa G, June CH. Abstract CT105: Safety and feasibility of chimeric antigen receptor modified T cells directed against mesothelin (CART-meso) in patients with mesothelin expressing cancers Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Ct105 |
0.668 |
|
| 2015 |
Maus MV. The ultimate combination immunotherapy Science Translational Medicine. 7: 279ec44-279ec44. DOI: 10.1126/Scitranslmed.Aaa9868 |
0.349 |
|
| 2015 |
Maus MV. T cells in a (polymer) matrix Science Translational Medicine. 7: 273ec21. DOI: 10.1126/Scitranslmed.Aaa5559 |
0.628 |
|
| 2015 |
O'Rourke D, Desai A, Morrissette J, Martinez-Lage M, Nasrallah M, Brem S, Maloney E, Shen A, Mohan S, Wang S, Verma G, Lacey S, Melenhorst J, Navenot J, Zheng Z, ... ... Maus M, et al. IMCT-15PILOT STUDY OF T CELLS REDIRECTED TO EGFRvIII WITH A CHIMERIC ANTIGEN RECEPTOR IN PATIENTS WITH EGFRvIII+ GLIOBLASTOMA Neuro-Oncology. 17: v110.4-v111. DOI: 10.1093/Neuonc/Nov218.15 |
0.666 |
|
| 2015 |
Kudchodkar SB, Tang L, Jeng EK, Wong HC, Irvine DJ, Maus MV. 517. Improving CAR T Cell Efficacy for Solid Tumors By Nanogel-Based Delivery of Immunomodulatory Proteins Molecular Therapy. 23: S207. DOI: 10.1016/S1525-0016(16)34126-0 |
0.637 |
|
| 2014 |
Johnson LA, Scholler J, Ohkuri T, Kosaka A, Patel PR, McGettigan SE, Nace A, Thekkat P, Loew A, Chen TJ, Fraietta JA, Posey AD, Boesteanu AC, Cogdill AP, Engels B, ... ... Maus M, et al. Pre-clinical validation of a humanized anti-EGFR variant III chimeric antigen receptor and phase I trial of CART-EGFRvIII in glioblastoma Journal For Immunotherapy of Cancer. 2: 1-1. PMID 25746013 DOI: 10.1186/2051-1426-2-S3-O1 |
0.647 |
|
| 2014 |
June CH, Maus MV, Plesa G, Johnson LA, Zhao Y, Levine BL, Grupp SA, Porter DL. Engineered T cells for cancer therapy. Cancer Immunology, Immunotherapy : Cii. 63: 969-75. PMID 24943274 DOI: 10.1007/S00262-014-1568-1 |
0.596 |
|
| 2014 |
Maus MV, June CH. CARTs on the road for myeloma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3899-901. PMID 24919574 DOI: 10.1158/1078-0432.Ccr-14-0721 |
0.697 |
|
| 2014 |
Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM, Kalos M, June CH. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunology Research. 2: 112-20. PMID 24579088 DOI: 10.1158/2326-6066.Cir-13-0170 |
0.693 |
|
| 2014 |
Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood. 123: 2625-35. PMID 24578504 DOI: 10.1182/Blood-2013-11-492231 |
0.691 |
|
| 2014 |
Maus MV, Fraietta JA, Levine BL, Kalos M, Zhao Y, June CH. Adoptive immunotherapy for cancer or viruses. Annual Review of Immunology. 32: 189-225. PMID 24423116 DOI: 10.1146/Annurev-Immunol-032713-120136 |
0.566 |
|
| 2014 |
Garfall AL, Fraietta JA, Maus MV. Immunotherapy with chimeric antigen receptors for multiple myeloma. Discovery Medicine. 17: 37-46. PMID 24411699 |
0.454 |
|
| 2014 |
Maus MV. Immunology: T cells through the age(s) Science Translational Medicine. 6. DOI: 10.1126/Scitranslmed.Aaa3460 |
0.536 |
|
| 2014 |
Maus MV. Immunology: T cells through the age(s) Science Translational Medicine. 6. DOI: 10.1126/scitranslmed.aaa3460 |
0.414 |
|
| 2014 |
Maus MV. CAR T Cells Advance to the Next Level Science Translational Medicine. 6: 261ec190-261ec190. DOI: 10.1126/Scitranslmed.Aaa1533 |
0.63 |
|
| 2014 |
Maus MV. A cancer drug promotes hair growth Science Translational Medicine. 6. DOI: 10.1126/Scitranslmed.3010412 |
0.48 |
|
| 2014 |
Maus MV. Hybrid CARs for Cancer? Science Translational Medicine. 6: 249ec139-249ec139. DOI: 10.1126/Scitranslmed.3010119 |
0.65 |
|
| 2014 |
Maus MV. Viewing T cell biology through a genomic lens Science Translational Medicine. 6. DOI: 10.1126/Scitranslmed.3009627 |
0.541 |
|
| 2014 |
Maus MV. The long-awaited marriage of cancer genomics and immunotherapy bears fruit Science Translational Medicine. 6. DOI: 10.1126/Scitranslmed.3009312 |
0.427 |
|
| 2014 |
Maus MV. The chicken or the egg? Checkpoint markers identify tumor-specific T cells in melanoma Science Translational Medicine. 6. DOI: 10.1126/Scitranslmed.3009047 |
0.512 |
|
| 2014 |
Maus MV. The chicken or the egg? Checkpoint markers identify tumor-specific T cells in melanoma Science Translational Medicine. 6. DOI: 10.1126/scitranslmed.3009047 |
0.437 |
|
| 2013 |
Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M, June CH. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunology Research. 1: 26-31. PMID 24777247 DOI: 10.1158/2326-6066.Cir-13-0006 |
0.689 |
|
| 2013 |
Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M, June CH. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunology Research. 1: 26-31. PMID 24432303 |
0.646 |
|
| 2013 |
Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, Litzky L, Bagg A, Carreno BM, Cimino PJ, Binder-Scholl GK, Smethurst DP, Gerry AB, Pumphrey NJ, Bennett AD, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 122: 863-71. PMID 23770775 DOI: 10.1182/Blood-2013-03-490565 |
0.697 |
|
| 2013 |
Maus MV, June CH. Zoom Zoom: racing CARs for multiple myeloma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 1917-9. PMID 23444214 DOI: 10.1158/1078-0432.Ccr-13-0168 |
0.692 |
|
| 2011 |
Maus MV, Riviere I, Borquez-Ojeda O, Wang X, Yuan J, Merghoub T, Plotkin J, O’Reilly RJ, Wolchok JD, Sadelain M. Artificial Antigen Presenting Cells Expand NY-ESO-1 Antigen-Specific CD8+ T Cells From Patients with Melanoma Blood. 118: 4309-4309. DOI: 10.1182/Blood.V118.21.4309.4309 |
0.669 |
|
| 2009 |
Pien GC, Basner-Tschakarjan E, Hui DJ, Mentlik AN, Finn JD, Hasbrouck NC, Zhou S, Murphy SL, Maus MV, Mingozzi F, Orange JS, High KA. Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. The Journal of Clinical Investigation. 119: 1688-95. PMID 19436115 DOI: 10.1172/Jci36891 |
0.418 |
|
| 2007 |
Zhang H, Snyder KM, Suhoski MM, Maus MV, Kapoor V, June CH, Mackall CL. 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy. Journal of Immunology (Baltimore, Md. : 1950). 179: 4910-8. PMID 17878391 DOI: 10.4049/Jimmunol.179.7.4910 |
0.791 |
|
| 2007 |
Mingozzi F, Maus MV, Hui DJ, Sabatino DE, Murphy SL, Rasko JE, Ragni MV, Manno CS, Sommer J, Jiang H, Pierce GF, Ertl HC, High KA. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nature Medicine. 13: 419-22. PMID 17369837 DOI: 10.1038/Nm1549 |
0.538 |
|
| 2007 |
Pien GC, Hasbrouck NC, Maus MV, Mingozzi F, High KA. Quantifying Capsid Peptide:MHC I Complexes Following Adeno-Associated Virus (AAV) Transduction Blood. 110: 3737-3737. DOI: 10.1182/Blood.V110.11.3737.3737 |
0.489 |
|
| 2006 |
Mingozzi F, Maus MV, Sabatino DE, Hui DJ, Rasko JE, Ragni MV, Manno CS, Ertl HC, High KA. AAV-2 Capsid-Specific CD8+ T Cells Limit the Duration of Gene Therapy in Humans and Cross-React with AAV-8 Capsid. Blood. 108: 455-455. DOI: 10.1182/Blood.V108.11.455.455 |
0.64 |
|
| 2006 |
Hui DJ, Mingozzi F, Maus MV, Tigges MA, Pierce GF, High KA. A Novel Splenocyte Approach for Characterizing T Cell Responses to Adeno-Associated Virus in the Normal Population: Implications on Gene Transfer. Blood. 108: 3258-3258. DOI: 10.1182/Blood.V108.11.3258.3258 |
0.595 |
|
| 2006 |
Maus MV, Mingozzi F, Sabatino DE, Hui D, Ragni MV, High KA. 730. T Cell Responses to AAV Vector Capsid in Normal Donors and Subjects Who Have Undergone Liver-Directed AAV-Mediated Gene Transfer Molecular Therapy. 13: S282. DOI: 10.1016/J.Ymthe.2006.08.810 |
0.634 |
|
| 2005 |
Mingozzi F, Maus MV, Sabatino DE, Hui D, Manno CS, Ragni MV, High KA. T Cell Responses to AAV Vector Capsid Limit the Duration of Transgene Expression in Humans after Liver-Directed Gene Therapy. Blood. 106: 3055-3055. DOI: 10.1182/Blood.V106.11.3055.3055 |
0.595 |
|
| 2004 |
Maus MV, Kovacs B, Kwok WW, Nepom GT, Schlienger K, Riley JL, Allman D, Finkel TH, June CH. Extensive replicative capacity of human central memory T cells. Journal of Immunology (Baltimore, Md. : 1950). 172: 6675-83. PMID 15153483 DOI: 10.4049/Jimmunol.172.11.6675 |
0.663 |
|
| 2003 |
Oelke M, Maus MV, Didiano D, June CH, Mackensen A, Schneck JP. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nature Medicine. 9: 619-24. PMID 12704385 DOI: 10.1038/Nm869 |
0.623 |
|
| 2003 |
Schlienger K, Chu CS, Woo EY, Rivers PM, Toll AJ, Hudson B, Maus MV, Riley JL, Choi Y, Coukos G, Kaiser LR, Rubin SC, Levine BL, Carroll RG, June CH. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 1517-27. PMID 12684428 |
0.581 |
|
| 2003 |
Maus MV, Riley JL, Kwok WW, Nepom GT, June CH. HLA tetramer-based artificial antigen-presenting cells for stimulation of CD4+ T cells. Clinical Immunology (Orlando, Fla.). 106: 16-22. PMID 12584046 DOI: 10.1016/S1521-6616(02)00017-7 |
0.684 |
|
| 2002 |
Thomas AK, Maus MV, Shalaby WS, June CH, Riley JL. A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes. Clinical Immunology (Orlando, Fla.). 105: 259-72. PMID 12498807 DOI: 10.1006/Clim.2002.5277 |
0.612 |
|
| 2002 |
Kovacs B, Maus MV, Riley JL, Derimanov GS, Koretzky GA, June CH, Finkel TH. Human CD8+ T cells do not require the polarization of lipid rafts for activation and proliferation. Proceedings of the National Academy of Sciences of the United States of America. 99: 15006-11. PMID 12419850 DOI: 10.1073/Pnas.232058599 |
0.62 |
|
| 2002 |
Maus MV, Thomas AK, Leonard DG, Allman D, Addya K, Schlienger K, Riley JL, June CH. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nature Biotechnology. 20: 143-8. PMID 11821859 DOI: 10.1038/Nbt0202-143 |
0.713 |
|
| Show low-probability matches. |